logo
Plus   Neg
Share
Email

Santos Q3 Production Flat; Narrows FY Production And Sales Volumes Guidance

Santos Ltd. (STOSF.PK,SSLTY.PK,STO.AX) reported that its third quarter production was 15 million barrels of oil equivalent or mmboe, same with last year. Sales revenue grew 22.7% year-over-year to US$973 million, including record quarterly LNG revenues of US$405 million.

Santos Managing Director and Chief Executive Officer Kevin Gallagher said, "Santos' third quarter results serve to highlight the benefits of a cash generative core asset portfolio and our low-cost, disciplined Operating Model. During the quarter we paid our first dividend in two and a half years and achieved our net debt target of $2 billion more than a year ahead of plan."

Santos said it is now positioned for growth with a number of upstream brownfield development opportunities leveraging existing infrastructure positions across each of our five core assets and is targeting production of more than 100 mmboe by 2025, almost doubling current levels of production.

Santos raised the lower end of its 2018 production outlook to 56-58 mmboe from 55-58 mmboe. The sales volume is expected to be in the range of 74-76 mmboe compared to the prior outlook of 72-76 mmboe.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration granted emergency use authorization (EUA) for the first and only clinical T cell-based test for patients to detect the unique T-cell signature specific to SARS-CoV-2, the virus that causes COVID-19. The test confirms recent or prior COVID-19 infection. Developed by Adaptive Biotechnologies, T-Detect COVID Test is a next generation sequencing based (NGS) test. AstraZeneca's one batch of Covid vaccine has been suspended by Austrian health authorities following reports of a death and an illness after receiving vaccination, reports said. The issues were reported in the district clinic of Zwettl in Lower Austria province. The Federal Office for Safety in Health Care in the country said the remaining stocks of the affected AstraZeneca/Oxford Covid-19 vaccine DuPont (DD) announced Monday that it has agreed to acquire Laird Performance Materials from with private equity firm Advent International for $2.3 billion. The company will use existing cash balances for the acquisition. The transaction is expected to close in the third quarter of 2021, subject to regulatory...
RELATED NEWS
Follow RTT